Bifeprunox is a novel atypical antipsychotic agent which, along with SLV313, aripiprazole and SSR-181507 combines minimal D2 receptor agonism with 5-HT receptor agonism.
- Mechanism
- Curator reviewed
In contrast to D2 receptor antagonism, partial D2 agonism is believed to decrease dopamine activity in an overactive dopamine system while simultaneously increasing dopamine activity in regions of the brain where dopaminergic activity is too low. By blocking overstimulated receptors and stimulating underactive ones, partial D2 agonists act as dopamine stabilisers. In common with aripiprazole, bifeprunox also acts as a serotonin, 5-HT1A agonist. This property may contribute to efficacy against the negative symptoms of schizophrenia and reduce the likelihood of extrapyramidal symptoms (EPS).
- Primary indication
- Bifeprunox is being evaluated for the treatment of schizophrenia, psychosis, and Parkinson's disease.Curator reviewed
- Formula / weight
- C24H23N3O2 · 385.4583 g/mol (avg)
- Code names
- DU-127090
Resolves to
CYGODHVAJQTCBG-UHFFFAOYSA-NSMILESO=C1NC2=C(O1)C(=CC=C2)N1CCN(CC2=CC(=CC=C2)C2=CC=CC=C2)CC1What you can answer from here — as of September 23, 2026
Which drugs share a target with Bifeprunox, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account